Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $829K | $1.08M | $963K | $1.18M | $1.82M | $386K | $81.5K | $0.00 | $3.95M | $2.49M |
| Revenue growth | — | 29.7% | -10.4% | 22.1% | 55.1% | -78.9% | -78.9% | -100.0% | — | -37.1% |
| Operating income | -$3.27M | -$2.17M | -$2.56M | -$2.37M | -$2.82M | -$18.7M | -$14.0M | -$26.7M | -$25.1M | -$21.6M |
| Operating margin | -394.9% | -202.2% | -266.1% | -201.8% | -154.5% | -4862.7% | -17207.5% | — | -635.8% | -869.3% |
| Net income | -$3.27M | -$2.17M | -$2.56M | -$2.37M | -$2.96M | -$18.6M | -$14.0M | -$26.0M | -$25.0M | -$21.5M |
| Net margin | -394.7% | -201.8% | -265.8% | -201.6% | -162.2% | -4817.2% | -17198.3% | — | -632.0% | -862.3% |
| EPS (diluted) | -$0.08 | -$0.03 | -$15,610.33 | -$781.87 | -$2.14 | -$3.04 | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.95M | -$1.69M | -$1.54M | -$1.40M | -$2.75M | -$11.2M | -$19.0M | -$25.2M | -$24.7M | -$21.5M |
| Capital expenditures | — | $4.35K | — | $7.61K | $157K | $47.7K | $134K | $48.9K | $20.7K | $27.6K |
| Free cash flow | — | -$1.69M | — | -$1.41M | -$2.91M | -$11.2M | -$19.2M | -$25.2M | -$24.7M | -$21.5M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $454K | $313K | $260K | $283K | $9.88M | $11.4M | $27.6M | $6.45M | $5.51M | $3.09M |
| Total assets | $610K | $490K | $642K | $469K | $10.4M | $11.8M | $31.3M | $9.28M | $8.16M | $6.34M |
| Total liabilities | — | $811K | $1.66M | $2.04M | $825K | $7.44M | $4.75M | — | $3.11M | $2.52M |
| Shareholders' equity | $240K | -$321K | -$1.02M | -$1.57M | $9.57M | $4.36M | $26.6M | $5.76M | $5.05M | $3.83M |
| Retained earnings | -$35.7M | -$37.9M | -$40.5M | -$42.8M | -$45.8M | -$64.4M | -$78.4M | -$104M | -$129M | -$151M |
| Shares (wtd avg diluted) | 55.2M | 107M | 219M | 15.0B | 3.83M | 6.10M | 1.13M | 1.82M | 207K | 958K |
Every figure is extracted from GeoVax Labs, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.